<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00464893</url>
  </required_header>
  <id_info>
    <org_study_id>IP-CAT-GC-03</org_study_id>
    <secondary_id>EudraCT-Nr.:2006-002727-16</secondary_id>
    <nct_id>NCT00464893</nct_id>
  </id_info>
  <brief_title>Phase II Study With Catumaxomab in Patients With Gastric Cancer After Neoadjuvant CTx and Curative Resection</brief_title>
  <official_title>Multicenter, Open-label Phase II Study to Evaluate the Safety and Efficacy of the Trifunctional Bispecific Antibody Catumaxomab (Anti-EpCAM x Anti-CD3) in Patients With Gastric Adenocarcinoma After Neoadjuvant Chemotherapy and Intended Curative Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neovii Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neovii Biotech</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary evaluation of the safety, tolerability and feasibility regarding specific&#xD;
      postoperative complications of an adjuvant treatment with catumaxomab administered after&#xD;
      curative tumor resection subsequent to a neoadjuvant chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label, multi-center phase II study in surgically resectable patients after&#xD;
      neoadjuvant ECX-chemotherapy, with confirmed diagnosis of gastric adenocarcinoma and with a&#xD;
      high risk of disseminated tumor cells due to serosal infiltration or positive lymph nodes&#xD;
      after curative gastrectomy.&#xD;
&#xD;
      Treatment with catumaxomab will consist of an initial dose of 10 µg given intraoperatively as&#xD;
      an intraperitoneal bolus and of four postoperative ascending doses (10-20-50-150 µg)which&#xD;
      will be administered as an i.p.-infusion using an installed abdominal i.p.-port on the&#xD;
      postoperative days 7, 10, 13 and 16.&#xD;
&#xD;
      Catumaxomab is a trifunctional antibody targeting EpCAM on tumor cells and CD3 on T cells.&#xD;
      Trifunctional antibodies represent a new concept for targeted anticancer therapy. This new&#xD;
      antibody class has the capability to redirect T cells and accessory cells (e.g. macrophages,&#xD;
      dendritic cells [DCs] and natural killer [NK] cells) to the tumor site. According to&#xD;
      preclinical data, trifunctional antibodies activate these different immune effector cells,&#xD;
      which can trigger a complex anti-tumor immune response.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rate of all specific postoperative complications newly observed during a period of 30 days after surgery in those study patients who received at least the first 3 doses of catumaxomab</measure>
    <time_frame>30 days after last catumaxomab administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>frequency, relationship and seriousness of adverse events</measure>
    <time_frame>30 days after last catumaxomab administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>surgical resection rate</measure>
    <time_frame>after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chemotherapeutic response rate</measure>
    <time_frame>after neoadjuvant CTx</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival at 3, 6, 9, 12 and 24 month after EOT, defined as the time from study enrolment until death</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease-free survival at 3, 6, 9, 12 18 and 24 months after EOT, defined as the time from study enrolment to the point of diagnosis of recurrent disease or death, whichever occurred first</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Gastric Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>catumaxomab arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will get first the chemotherapeutic regimen (Epirubicin, Cisplatin and Capecitabine or 5-Fluorouracil) consisting of three 21-day cycles, starting on the weeks 1, 4 and 7. Four weeks after CTx the D2 surgery will take place. Treatment with catumaxomab will consist of an initial dose of 10µg given intraoperatively as in intraperitoneal bolus and of four postoperative ascending doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Catumaxomab</intervention_name>
    <description>10 µg intraoperative and 4 ascending doses (10, 20, 50 and 150 µg) on day 7, 10, 13 and 16</description>
    <arm_group_label>catumaxomab arm</arm_group_label>
    <other_name>Removab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>catumaxomab</intervention_name>
    <description>10 µg intraoperatively and 4 ascending doses: 10, 20, 50 and 150 µg</description>
    <arm_group_label>catumaxomab arm</arm_group_label>
    <other_name>Removab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  signed and dated informed consent&#xD;
&#xD;
          -  male or female patient at an age of 18 years or older&#xD;
&#xD;
          -  patient has a primary diagnosis of a histologically confirmed gastric adenocarcinoma&#xD;
             (including GE junction Siewert-Type 2 or 3)&#xD;
&#xD;
          -  TNM-staging at screening of T3/T4, N+/-, M0 or T2, N+, M0&#xD;
&#xD;
          -  indication and eligibility for a neoadjuvant chemotherapeutic regimen featuring three&#xD;
             cycles of ECX with 21 days per cycle&#xD;
&#xD;
          -  intended curative gastrectomy&#xD;
&#xD;
          -  Karnofsky index &gt; 70&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exposure to prior cancer therapy or planned adjuvant chemo- or radiotherapy of the&#xD;
             current gastric cancer&#xD;
&#xD;
          -  prior diagnosis of any malignancy not cured by surgery alone less than 5 years before&#xD;
             study entry&#xD;
&#xD;
          -  previous use of non-humanized monoclonal mouse or rat antibodies&#xD;
&#xD;
          -  treatment with another investigational product during this study or during the last 30&#xD;
             days prior to study start&#xD;
&#xD;
          -  presence of distant metastases&#xD;
&#xD;
          -  presence of constant immunosuppressive therapy&#xD;
&#xD;
          -  history of pancreas resection (also partial) or thoracotomy&#xD;
&#xD;
          -  presence of any acute or chronic systemic infection&#xD;
&#xD;
          -  patient with a bowel obstruction within the last 30 days&#xD;
&#xD;
          -  known contraindications to any of the planned ECX chemotherapeutics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carsten Bokemeyer, Prof MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Clinic of Hamburg-Eppendorf; 20246 Hamburg / Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg, Berlin, Heidelberg, Köln, Halle</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Terrassa</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Heiss MM, Ströhlein MA, Jäger M, Kimmig R, Burges A, Schoberth A, Jauch KW, Schildberg FW, Lindhofer H. Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer. 2005 Nov 10;117(3):435-43.</citation>
    <PMID>15906359</PMID>
  </reference>
  <reference>
    <citation>Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood. 2001 Oct 15;98(8):2526-34.</citation>
    <PMID>11588051</PMID>
  </reference>
  <reference>
    <citation>Riesenberg R, Buchner A, Pohla H, Lindhofer H. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3). J Histochem Cytochem. 2001 Jul;49(7):911-7.</citation>
    <PMID>11410615</PMID>
  </reference>
  <reference>
    <citation>Zeidler R, Mysliwietz J, Csánady M, Walz A, Ziegler I, Schmitt B, Wollenberg B, Lindhofer H. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer. 2000 Jul;83(2):261-6.</citation>
    <PMID>10901380</PMID>
  </reference>
  <reference>
    <citation>Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, Lindhofer H. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol. 1999 Aug 1;163(3):1246-52.</citation>
    <PMID>10415020</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>April 23, 2007</study_first_submitted>
  <study_first_submitted_qc>April 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2007</study_first_posted>
  <last_update_submitted>December 3, 2013</last_update_submitted>
  <last_update_submitted_qc>December 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gastric cancer</keyword>
  <keyword>catumaxomab</keyword>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>phase II</keyword>
  <keyword>interoperative</keyword>
  <keyword>trifunctional antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Catumaxomab</mesh_term>
    <mesh_term>Antibodies, Bispecific</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

